Nektar Therapeutics NKTR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$164.08M-30.0% | -$126.22M+54.3% | -$276.06M+25.0% | -$368.2M+29.7% | ||
| $1.03M-76.6% | $4.39M-43.8% | $7.82M-40.0% | $13.03M-7.9% | ||
| $12.65M-41.5% | $21.61M-35.3% | $33.39M-41.8% | $57.32M-39.5% | ||
| -$208.51M-18.7% | -$175.71M+8.8% | -$192.61M+36.6% | -$304.01M+26.3% | ||
| $171K-88.4% | $1.47M+69.7% | $865K-84.8% | $5.68M-62.1% | ||
| —— | $142.57M+2.2% | $139.56M-61.9% | $365.84M+79.7% | ||
| $180.57M+329% | $42.12M+140,293% | $30K-98.0% | $1.51M-95.8% | ||
| —— | $8.98M— | —— | —— | ||
| -$208.68M-17.8% | -$177.18M+8.4% | -$193.47M+37.5% | -$309.68M+27.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.